The intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission, the company stated.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/EztvXSf
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bharat Biotech's COVID-19 nasal vaccine completes clinical development of phase III trials and booster doses
https://ift.tt/pdrG4v3
No comments:
Post a Comment